Join us in welcoming Boaz Mendzelevski, MD; Anupam Agarwal, MD, MPH; and Mary Beth Sabol, MD, BSN to CSRC committees. Drs. Mendzelevski and Agarwal joined the Scientific Oversight Committee and Dr. Sabol is now serving as the co-chair of the Membership Committee. Learn more about these members and their expertise by reading their biographies below.
Boaz Mendzelevski, MD:
Dr. Medzelevski is a consultant cardiologist at Cardiac Safety Consultants Ltd.
He received his degree in medicine from the Ben-Gurion University Medical School and his board certification in internal medicine from the Soroka Medical Center, both located in Beer-Sheva, Israel. He then obtained his board certification in cardiology from the Shaare-Zedek Medical Centre in Jerusalem, Israel. He completed further training in interventional cardiology and electrophysiology at the Royal Brompton Hospital and the National Heart and Lung Institute in London, UK.
Dr. Mendzelevski co-founded the first European pharmaceutical research ECG core laboratory, Cardiac Alert Ltd, in London, UK. It was later acquired by Quintiles, now known as IQVIA. He helped relocate and reinstate the lab in Mumbai, India, where it still operates today. Dr. Mendzelevski later joined Covance and launched its European Cardiac Safety Services group and, after the Covance ECG lab was divested, he joined Medifacts International, later becoming a part of the BioClinica organization, as Vice President of Cardiology.
Currently, Dr. Mendzelevski is focusing on his work as a cardiology consultant to the pharmaceutical and biotechnology industry and provides expert input regarding cardiovascular safety issues in drug development. He is also very active at the Drug Information Association (DIA) and chaired numerous DIA cardiac safety conferences and workshops in the United States, Europe, and Asia (Japan and China). He is a regular speaker and chair at other industry and scientific meetings and has authored numerous peer reviewed publications.
Anupam Agarwal, MD, MPH:
Dr. Agarwal is a cardiologist with over two decades of experience in treating patients and clinical research in academia in the United States. In the early 90s Dr. Agarwal worked at the Myocardial Infarction Triage and Intervention (MITI) registry with Douglas Weaver at the University of Washington, Seattle. In 2004-2005, he was associate director of Angiography Core Lab at TIMI Study Group at Brigham and Women’s Hospital. Over the span of his career, he was involved with research in genetics of hypertension, drug eluted coronary stents, and drug trials in many therapeutic areas including cardiovascular, respiratory, anti-inflammatory, GI, oncology, and Alzheimer’s disease. Dr. Agarwal has worked in the pharmaceutical industry for more than 11 years (GlaxoSmithKline, Pfizer, Gilead). He is currently the head of the Global Clinical Safety & Pharmacovigilance at Zogenix Inc., a pharmaceutical company developing therapies for rare diseases and central nervous system disorders.
Dr. Agarwal holds a medical degree from the GSVM Medical College, Kanpur, India and a Master of Public Health degree from the Harvard School of Public Health.
Mary Beth Sabol, MD, BSN:
Dr. Sabol is a cardiologist with experience in both academic medicine and industry. In the early 2000s, she was a Clinical Assistant Professor of Medicine at the hospital of the University of Pennsylvania and was Assistant Director of the Cardiovascular Nuclear Stress Lab. She subsequently joined Wyeth, then Pfizer, and worked in several different functional areas, including Medical Affairs as the Cardiovascular Therapeutic Area Head, Clinical Research & Development, and then Clinical and Post-Marketing Safety. Her experience includes working in multiple therapeutic areas, including cardiovascular, metabolic, endocrine, infectious diseases and transplantation. Since joining GSK in early 2011, Dr. Sabol has worked in Global Clinical Safety and Pharmacovigilance. She led the development and implementation of eCRFs for cardiovascular events and death to standardize data collection across clinical trials internally within GSK and then subsequently led a similar working group on behalf of CSRC. She is the GSK Clinical Safety representative to PhRMA. Within GSK, she co-chairs the Cardiology Safety Panel and is a member of the QT Safety Panel, the Non-Clinical Cardiovascular Safety Panel, the Central Safety Department Operations Board, and the Safety Advisory Forum.
Dr. Sabol received her BS degree in nursing from the University of Delaware and MD degree from Jefferson Medical College. She completed her residency in internal medicine from the University of Massachusetts Medical Center and fellowships in cardiovascular medicine from Thomas Jefferson University Hospital and in Nuclear Medicine from the Hospital of the University of Pennsylvania.